AEON Biopharma Inc. has released a corporate presentation detailing its development of ABP-450, a 900kD botulinum toxin being developed as a biosimilar to Botox®. The presentation highlights AEON's strategic efforts to address persistent cost-related barriers in the market, such as high out-of-pocket costs for patients and product margin concerns for physicians. The company is progressing with its Comparative Analytical Assessment $(CAA)$ studies, which began in Q4 2024, and is targeting an FDA BPD Type 2a meeting in the second half of 2025. The presentation outlines AEON's readiness to reshape access in a market currently dominated by Botox®. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.